Praxis Precision Medicines, Inc. PRAX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $267.12M+75.3% | $152.41M+75.7% | $86.77M-44.0% | $155.04M+28.9% | ||
| $59.08M+4.9% | $56.31M+33.9% | $42.05M-29.8% | $59.95M+27.3% | ||
| $326.2M+56.3% | $208.72M+62.0% | $128.82M-40.1% | $214.99M+28.5% | ||
| $326.2M+56.3% | $208.72M+62.0% | $128.82M-40.1% | $214.99M+28.5% | ||
| -$326.2M-63.0% | -$200.17M-58.4% | -$126.37M+41.2% | -$214.99M-28.5% | ||
| $22.93M+32.2% | $17.35M+460% | $3.1M+224% | $957K+253% | ||
| -$303.27M-65.9% | -$182.82M-48.3% | -$123.28M+42.4% | -$214.03M-28.1% | ||
| -$13.47-30.4% | -$10.33+54.4% | -$22.64+67.5% | -$69.65-1,677% | ||
| -$13.47-30.4% | -$10.33+54.4% | -$22.64+67.5% | -$69.65-1,677% | ||
| 87M+25.2% | 69.5M+192% | 23.8M-83.0% | 139.8M-16.4% | ||
| 87M+25.2% | 69.5M+192% | 23.8M-83.0% | 139.8M-16.4% | ||
| $22.93M+32.2% | $17.35M+460% | $3.1M+224% | $957K— | ||
| -$326.2M-63.0% | -$200.17M-58.4% | -$126.37M+41.2% | -$214.99M-28.5% | ||
| -$326.06M-63.2% | -$199.81M-58.7% | -$125.94M+41.3% | -$214.57M-28.4% | ||
| -$326.06M-63.2% | -$199.81M-58.7% | -$125.94M+41.3% | -$214.57M-28.4% | ||
| -$326.2M-63.0% | -$200.17M-58.4% | -$126.37M+41.2% | -$214.99M-28.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Praxis Precision Medicines, Inc. profitable?
- Praxis Precision Medicines, Inc. is not currently profitable: it reported a net loss of $326.5M over the trailing twelve months, a -3658.5% net margin.
- What is Praxis Precision Medicines, Inc.'s earnings per share?
- Praxis Precision Medicines, Inc.'s diluted EPS over the trailing twelve months is $-13.38.
- Where does Praxis Precision Medicines, Inc.'s income statement data come from?
- Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.